XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 30.98

+3.9%

Dec 3 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Arthur Radley who wrote (16226)	7/9/2003 4:11:11 PM
From: Edscharp	Read Replies (1) of 17367

Tex, Interesting article. You have to wonder about the perceived efficacy of neuprex if Baxter is willing to pay $10M to get it off their books. On the other, this is a brilliant coup for Xoma. Squeezing $10M+ out of Baxter is probably the biggest return anybody has ever gotten for a failed drug. A hearty congratulations to Xoma management is in order. This is a brilliant concept. Why worry about making approvable efficacious drugs when there is good money to be made on the non-approvable variety? I believe this new philosophy may turn the biotech world upside down. <g>

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next